肝细胞癌患者恶病质普遍存在且与不良预后相关
这项回顾性队列研究纳入两个美国医疗系统2008至2018年诊断的604例肝细胞癌患者,发现诊断时23.7%存在恶病质、33.3%存在前恶病质。恶病质患者接受抗肿瘤治疗的可能性更低,生存期更短,且在校正多因素后仍独立与更差生存相关。
要点
- 肝细胞癌诊断时近1/4患者存在恶病质,1/3存在前恶病质。
- 恶病质患者接受肝细胞癌治疗的可能性更低(OR 0.38)。
- 恶病质独立预测更差生存(HR 1.43),应早期识别。
核心结论
- 肝细胞癌患者诊断时恶病质普遍存在,且是不良预后的早期独立预测因素。
研究设计与样本
- 回顾性队列研究,纳入2008至2018年美国两个医疗系统诊断的604例肝细胞癌患者。
- 记录诊断前6个月及诊断时体重,恶病质定义为体重丢失>5%(BMI<20 kg/m2时>2%),前恶病质定义为体重丢失2%至5%。
- 采用多因素logistic回归分析恶病质相关因素,多因素Cox比例风险模型分析总生存相关因素。
主要发现
- 604例患者中,201例(33.3%)存在前恶病质,143例(23.7%)存在恶病质。
- BCLC 0/A、B、C、D期患者恶病质比例分别为19.0%、23.5%、34.7%、34.0%。
- 恶病质患者接受肝细胞癌治疗的可能性更低(OR 0.38,95%CI 0.21-0.71)。
- 恶病质、前恶病质、体重稳定患者生存期分别为11.3、20.4、23.5个月(P<.001)。
- 校正年龄、性别、种族、民族、Child-Pugh分级、甲胎蛋白、BCLC分期及肝细胞癌治疗后,恶病质仍独立与更差生存相关(HR 1.43,95%CI 1.11-1.84)。
临床怎么用
- 对肝细胞癌患者应在诊断时常规评估体重变化,识别恶病质和前恶病质。
- 恶病质提示预后不良且可能影响治疗接受度,应纳入预后评估和临床决策。
局限性
- 回顾性队列研究设计,可能存在选择偏倚和残余混杂。
- 仅纳入两个美国医疗系统患者,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Cancer cachexia is a wasting syndrome associated with functional impairment and reduced survival that impacts up to 50% of patients with gastrointestinal cancers. However, data are limited on the prevalence and clinical significance of cachexia in patients with hepatocellular carcinoma (HCC). METHODS: We performed a retrospective cohort study of patients diagnosed with HCC at 2 United States health systems between 2008 and 2018. Patient weights were recorded 6 months prior to and at time of HCC diagnosis. Cachexia was defined as >5% weight loss (or >2% weight loss if body mass index <20 kg/m2), and precachexia was defined as 2% to 5% weight loss. We used multivariable logistic regression models to identify correlates of cachexia and multivariable Cox proportional hazard models to identify factors associated with overall survival. RESULTS: Of 604 patients with HCC, 201 (33.3%) had precachexia and 143 (23.7%) had cachexia at diagnosis, including 19.0%, 23.5%, 34.7%, and 34.0% of patients with Barcelona Clinic Liver Cancer stages 0/A, B, C, and D, respectively. Patients with cachexia were less likely to receive HCC treatment (odds ratio, 0.38; 95% confidence interval, 0.21-0.71) and had worse survival than those with precachexia or stable weight (11.3 vs 20.4 vs 23.5 months, respectively; P < .001). Cachexia remained independently associated with worse survival (hazard ratio, 1.43; 95% confidence interval, 1.11-1.84) after adjusting for age, sex, race, ethnicity, Child Pugh class, alpha-fetoprotein, Barcelona Clinic Liver Cancer stage, and HCC treatment. CONCLUSIONS: Nearly 1 in 4 patients with HCC present with cachexia, including many with compensated cirrhosis or early stage tumors. The presence of cancer-associated weight loss appears to be an early and independent predictor of worse outcomes in patients with HCC.
引用
- Rich NE, Phen S, Desai N, et al. Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. Clin Gastroenterol Hepatol. 2021. PMID: 34555519. doi:10.1016/j.cgh.2021.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。